PriceTargets.com logo

GreenLight Biosciences - GRNA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $4.75
  • Forecasted Upside: 1,485.98%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.30 As of 08/14/2023 01:00 AM ET
+0 (0.00%)
Get New GreenLight Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRNA

Analyst Price Target is $4.75
▲ +1,485.98% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for GreenLight Biosciences in the last 3 months. The average price target is $4.75, with a high forecast of $5.50 and a low forecast of $4.00. The average price target represents a 1,485.98% upside from the last price of $0.30.

This chart shows the closing price for GRNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 2 investment analysts is to moderate buy stock in GreenLight Biosciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2023Credit Suisse GroupDowngradeOutperform ➝ NeutralLow
12/8/2022Canaccord Genuity GroupInitiated CoverageBuy$4.00Low
10/14/2022Credit Suisse GroupInitiated CoverageOutperform$5.50Low
(Data available from 9/28/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/30/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
GreenLight Biosciences logo
FUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.
Read More

Today's Range

Now: $0.30
Low: $0.30
High: $0.30

50 Day Range

MA: $0.30
Low: $0.30
High: $0.30

52 Week Range

Now: $0.30
Low: $0.18
High: $5.90

Volume

732 shs

Average Volume

486,986 shs

Market Capitalization

$45.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Frequently Asked Questions

What sell-side analysts currently cover shares of GreenLight Biosciences?

The following equities research analysts have issued research reports on GreenLight Biosciences in the last twelve months: Canaccord Genuity Group Inc., and Credit Suisse Group AG.
View the latest analyst ratings for GRNA.

What is the current price target for GreenLight Biosciences?

2 Wall Street analysts have set twelve-month price targets for GreenLight Biosciences in the last year. Their average twelve-month price target is $4.75, suggesting a possible upside of 1,486.0%. Credit Suisse Group AG has the highest price target set, predicting GRNA will reach $5.50 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $4.00 for GreenLight Biosciences in the next year.
View the latest price targets for GRNA.

What is the current consensus analyst rating for GreenLight Biosciences?

GreenLight Biosciences currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for GRNA.

What other companies compete with GreenLight Biosciences?

Other companies that are similar to GreenLight Biosciences include MiNK Therapeutics, Precision BioSciences, Quince Therapeutics, Sorrento Therapeutics and OKYO Pharma. Learn More about companies similar to GreenLight Biosciences.

How do I contact GreenLight Biosciences' investor relations team?

GreenLight Biosciences' physical mailing address is 535 MADISON AVENUE, BOSTON NY, 02110. The company's listed phone number is (760) 809-8079 and its investor relations email address is [email protected]. The official website for GreenLight Biosciences is www.eiacorp.com. Learn More about contacing GreenLight Biosciences investor relations.